Chroma
Generative AI platform for designing novel therapeutic proteins
Platform · OtherCompany source
Company profile
About Generate Biomedicines
Generate Biomedicines is a biotechnology company at the forefront of applying generative artificial intelligence to therapeutic protein design and drug discovery. The company has developed a proprietary generative biology platform that uses machine learning to create novel protein therapeutics from scratch, rather than modifying existing proteins. This approach enables the design of proteins with specific therapeutic properties tailored to address unmet medical needs. Generate Biomedicines' technology platform combines deep learning, structural biology, and computational protein design to generate and optimize therapeutic candidates across multiple modalities including antibodies, peptides, and other protein-based drugs. The company's mission is to expand the druggable proteome and accelerate the development of breakthrough medicines. By leveraging generative AI, Generate Biomedicines aims to design proteins that are difficult or impossible to create using traditional methods, potentially unlocking new therapeutic opportunities across various disease areas. The company serves the biopharmaceutical industry and is developing its own pipeline of therapeutic candidates while also partnering with pharmaceutical companies to apply its platform to their drug discovery programs.
Company description Generate Biomedicines official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Work at Generate Biomedicines?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
No clinical focus areas are currently listed.
Who it serves
- Biotech
- Pharma
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
Company milestones
Platform expansion
Initiated global Phase 3 studies of GB-0895 for severe asthma. Reported Q1 2026 financial results. Expanded to 140,000+ square feet across Boynton Yards (Somerville) and Andover locations. Participated in Goldman Sachs 47th Annual Global Healthcare Conference (May 2026).
Partnerships
Recorded partners
No partners are currently listed.
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix.The Journal of infectious diseases · Jul 14, 2026
Persistence of memory: lifespan dynamics of the human antiviral antibody reactome.Nature communications · Jun 22, 2026
Characterizing Phytochrome Photochemistry Using UV-Visible Spectroscopy in Host Cell Extracts and Purified Protein.Methods in molecular biology (Clifton, N.J.) · Jan 1, 2026
Discovery of a small molecule TLR3 agonist adjuvant.Nature communications · Dec 4, 2025
Proteome-wide in silico screening for human protein-protein interactions.bioRxiv : the preprint server for biology · Nov 12, 2025
Monitoring Dynamic Conformations of a Single Fluorescent Molecule Inside a Protein Cavity.Small methods · Aug 1, 2025
Clinical validation
Clinical-trial records
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)NCT07276724 · Sponsor · RECRUITING
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)NCT07359846 · Sponsor · RECRUITING
GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube CancerNCT07489287 · Sponsor · RECRUITING
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial CancerNCT07484022 · Sponsor · RECRUITING
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult ParticipantsNCT06920693 · Sponsor · ACTIVE NOT RECRUITING
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPDNCT07116889 · Sponsor · ACTIVE NOT RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Michael Nally
Chief Executive Officer
Gevorg Grigoryan
Co-Founder & Chief Technology Officer
Jason Silvers
President & Chief Financial Officer
Aarif Khakoo
Chief Scientific Officer
Laurie Lee
Chief Medical Officer, Immunology & Inflammation
Sean Martin
Chief Legal Officer & General Counsel
Beth Grous
Chief People Officer
Dinesh de Alwis
Senior Vice President, Head of Clinical Drug Development
06 · Company updates
Updates from Generate Biomedicines
Recent articles published on Generate Biomedicines's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.